{"id":"https://openalex.org/W2564138697","doi":null,"title":"Significant Response to Gemcitabine Monotherapy in Primary Pleural Epithelioid Angiosarcoma","display_name":"Significant Response to Gemcitabine Monotherapy in Primary Pleural Epithelioid Angiosarcoma","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2564138697","mag":"2564138697"},"language":"en","primary_location":{"id":"mag:2564138697","doi":null,"is_oa":false,"landing_page_url":"https://www.jto.org/article/S1556-0864(15)32679-4/pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110503703","display_name":"Thean Hsiang Tan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thean Hsiang Tan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056074753","display_name":"Glenice Cheetham","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Glenice Cheetham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038779121","display_name":"Hamish S. Scott","orcid":"https://orcid.org/0000-0002-5813-631X","observed_orcids":["https://orcid.org/0000-0002-5813-631X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hamish S. Scott","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021075431","display_name":"Michael Paul Brown","orcid":"https://orcid.org/0000-0002-5796-1932","observed_orcids":["https://orcid.org/0000-0002-5796-1932","https://orcid.org/0000-0002-0495-7315"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael P. Brown","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5796-1932","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12278","display_name":"Vascular Tumors and Angiosarcomas","score":0.9307000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12278","display_name":"Vascular Tumors and Angiosarcomas","score":0.9307000041007996,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.037700001150369644,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10253","display_name":"Sarcoma Diagnosis and Treatment","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gemcitabine-monotherapy","display_name":"gemcitabine monotherapy","score":0.8370000123977661},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.527999997138977},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.824999988079071},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7680000066757202},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.7649999856948853},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9850000143051147},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.859000027179718},{"id":"https://openalex.org/keywords/lung-adenocarcinoma","display_name":"lung adenocarcinoma","score":0.7670000195503235},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.6349999904632568}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.919776201248169},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.8571729063987732},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.7546887397766113},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6884937882423401},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5863639116287231},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5451627373695374},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.4874279797077179},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.4642762541770935},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43536365032196045},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.43259188532829285},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42048829793930054},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4030578136444092},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.12724509835243225}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2564138697","doi":null,"is_oa":false,"landing_page_url":"https://www.jto.org/article/S1556-0864(15)32679-4/pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1970476748","https://openalex.org/W2002937040","https://openalex.org/W2005728761","https://openalex.org/W2070871717","https://openalex.org/W2117162062","https://openalex.org/W2121389354","https://openalex.org/W2150213614","https://openalex.org/W2154130790","https://openalex.org/W2159326739","https://openalex.org/W2170973522"],"related_works":["https://openalex.org/W1994626765","https://openalex.org/W2049033734","https://openalex.org/W2160081872","https://openalex.org/W7099968384","https://openalex.org/W2557984990","https://openalex.org/W2043696829","https://openalex.org/W1989503742","https://openalex.org/W1521346902","https://openalex.org/W2142364516","https://openalex.org/W2088294189"],"abstract_inverted_index":{"REFERENCES":[0],"1.":[1],"Lynch":[2],"TJ,":[3],"Bell":[4],"DW,":[5],"Sordella":[6],"R,":[7],"et":[8,39,72,175,199],"al.":[9,40,73,176,200],"Activating":[10],"mutations":[11,124,156,202],"in":[12,56,82,129,178,221],"the":[13,57],"epidermal":[14,76,91,120,151],"growth":[15,77,92,121,152],"factor":[16,78,93,122,153],"receptor":[17,94,123,154],"underlying":[18],"responsiveness":[19],"of":[20,43,75,114,125,150,185,206],"non-small-cell":[21],"lung":[22,44,87,132,179,207],"cancer":[23,88,180],"to":[24,46,209,218],"gefitinib.":[25],"N":[26,187],"Engl":[27,188],"J":[28,96,189],"Med":[29,62,190,214],"2004;350:":[30],"2129\u20132139.":[31],"2.":[32],"Pao":[33,193],"W,":[34,194],"Miller":[35],"VA,":[36],"Politi":[37],"KA,":[38],"Acquired":[41],"resistance":[42,205],"adenocarcinomas":[45,208],"gefitinib":[47,210],"or":[48,211],"erlotinib":[49],"is":[50],"associated":[51],"with":[52,84],"a":[53],"second":[54],"mutation":[55],"EGFR":[58,161],"kinase":[59,80,116],"domain.":[60],"PLoS":[61,213],"2005;2:e73.":[63],"3.":[64],"De":[65],"Pas":[66],"T,":[67],"Toffalorio":[68],"F,":[69],"Manzotti":[70],"M,":[71],"Activity":[74],"receptor-tyrosine":[79],"inhibitors":[81,117],"patients":[83],"non-small":[85],"cell":[86,131],"harboring":[89],"rare":[90],"mutations.":[95],"Thorac":[97],"Oncol":[98],"2011;6:1895\u20131901.":[99],"4.":[100],"Wu":[101],"JY,":[102,110],"Yu":[103],"CJ,":[104],"Chang":[105],"YC,":[106],"Yang":[107,111],"CH,":[108],"Shih":[109],"PC.":[112],"Effectiveness":[113],"tyrosine":[115],"on":[118],"\u201cuncommon\u201d":[119],"unknown":[126],"clinical":[127,183],"significance":[128],"nonsmall":[130],"cancer.":[133],"Clin":[134,164],"Cancer":[135,165],"Res":[136,166],"2011;17:3812\u20133821.":[137],"5.":[138],"Kancha":[139],"RK,":[140],"von":[141],"Bubnoff":[142],"N,":[143],"Peschel":[144],"C,":[145],"Duyster":[146],"J.":[147],"Functional":[148],"analysis":[149],"(EGFR)":[155],"and":[157,182,203],"potential":[158],"implications":[159],"for":[160],"targeted":[162],"therapy.":[163],"2009;15:460\u2013467.":[167],"6.":[168],"Tsao":[169],"MS,":[170],"Sakurada":[171],"A,":[172],"Cutz":[173],"JC,":[174],"Erlotinib":[177],"molecular":[181],"predictors":[184],"outcome.":[186],"2005;353:133\u2013144.":[191],"7.":[192],"Wang":[195],"TY,":[196],"Riely":[197],"GJ,":[198],"KRAS":[201],"primary":[204],"erlotinib.":[212],"2005;2:e17.":[215],"Significant":[216],"Response":[217],"Gemcitabine":[219],"Monotherapy":[220],"Primary":[222],"Pleural":[223],"Epithelioid":[224],"Angiosarcoma":[225]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-01-06T00:00:00"}